| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8733554 | Critical Reviews in Oncology/Hematology | 2018 | 6 Pages |
Abstract
Renal cell carcinoma (RCC) is classically regarded as extremely resistant to classical fractionated radiation therapy (RT). Nowadays, there is convincing data supporting RCC radiosensitivity to high fraction doses, which may represent an ideal issue for new treatment strategies in primary and oligometastatic RCC disease. This review discusses the role of RT in RCC and its potential therapeutic scenario focusing on the most interesting clinical trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Francesca De Felice, Vincenzo Tombolini,